Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008Monika Brüggemann, Yves Benoît, Andrea Biondi et al.|Leukemia|2009Cited by 338
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemiaKheïra Beldjord, Hervé Dombret, Sylvie Chevret et al.|Blood|2014Cited by 327
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangementsIlaria Tanasi, Emmanuelle Clappier, Ibrahima Ba et al.|Blood|2019Cited by 136
PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL studyJ Familiadès, Éric Delabesse, Marina Bousquet et al.|Leukemia|2009Cited by 122
Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALLRichard Garand, André Baruchel, Kheïra Beldjord et al.|Leukemia|2012Cited by 77